BR112017028516A2 - Sal de fumarato cristalino de (s)-[3,4-difluoro-2-(2- fluoro-4-iodofenilamino)fenil][3-hidroxi-3- (piperidin-2-il) azetidin-1-il]-metanona - Google Patents

Sal de fumarato cristalino de (s)-[3,4-difluoro-2-(2- fluoro-4-iodofenilamino)fenil][3-hidroxi-3- (piperidin-2-il) azetidin-1-il]-metanona

Info

Publication number
BR112017028516A2
BR112017028516A2 BR112017028516A BR112017028516A BR112017028516A2 BR 112017028516 A2 BR112017028516 A2 BR 112017028516A2 BR 112017028516 A BR112017028516 A BR 112017028516A BR 112017028516 A BR112017028516 A BR 112017028516A BR 112017028516 A2 BR112017028516 A2 BR 112017028516A2
Authority
BR
Brazil
Prior art keywords
azetidin
piperidin
difluoro
fluoro
hydroxy
Prior art date
Application number
BR112017028516A
Other languages
English (en)
Other versions
BR112017028516B1 (pt
Inventor
St Clair Brown Adrian
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017028516(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112017028516A2 publication Critical patent/BR112017028516A2/pt
Publication of BR112017028516B1 publication Critical patent/BR112017028516B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

esta divulgação refere-se ao sal de fumarato cristalino de (s)-[3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona. a divulgação também se refere a composições farmacêuticas compreendendo o sal de fumarato cristalino de (s)-[3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il) azetidin-1-il]-metanona. a divulgação também se refere a métodos de tratamento de cânceres compreendendo administrar a um paciente em necessidade do mesmo, o sal de fumarato cristalino de (s)- [3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil][3-hidroxi -3-(piperidin-2-il) azetidin-1-il]-metanona.
BR112017028516-9A 2015-06-30 2016-06-30 Sal de fumarato cristalino, seu uso, processo de preparação do mesmo e composição farmacêutica BR112017028516B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187009P 2015-06-30 2015-06-30
US62/187,009 2015-06-30
PCT/US2016/040444 WO2017004393A1 (en) 2015-06-30 2016-06-30 Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone

Publications (2)

Publication Number Publication Date
BR112017028516A2 true BR112017028516A2 (pt) 2018-08-28
BR112017028516B1 BR112017028516B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
JP2018519318A (ja) 2018-07-19
AU2016288209A1 (en) 2018-02-08
CA2990222C (en) 2023-09-26
RU2018103172A3 (pt) 2019-10-31
RU2018103172A (ru) 2019-07-31
CO2018000086A2 (es) 2018-04-10
JP7338950B2 (ja) 2023-09-05
US20200255398A1 (en) 2020-08-13
RU2762181C2 (ru) 2021-12-16
CL2017003475A1 (es) 2018-07-13
EP3317264A1 (en) 2018-05-09
AU2021200202A1 (en) 2021-03-18
TW201718535A (zh) 2017-06-01
IL295052A (en) 2022-09-01
MY192545A (en) 2022-08-26
US20180346442A1 (en) 2018-12-06
PE20180692A1 (es) 2018-04-23
UA124728C2 (uk) 2021-11-10
TWI710556B (zh) 2020-11-21
AU2016288209B2 (en) 2020-10-22
CA2990222A1 (en) 2017-01-05
CN118290395A (zh) 2024-07-05
TW202108568A (zh) 2021-03-01
US10590102B2 (en) 2020-03-17
JP2023025000A (ja) 2023-02-21
SG10202105196YA (en) 2021-06-29
RU2021132394A (ru) 2021-11-18
KR20180021775A (ko) 2018-03-05
ZA201708760B (en) 2022-06-29
WO2017004393A1 (en) 2017-01-05
IL256423B (en) 2022-09-01
MX2017017037A (es) 2018-04-30
JP2021035967A (ja) 2021-03-04
HK1252433A1 (zh) 2019-05-24
CN107810183A (zh) 2018-03-16
AU2021200202B2 (en) 2022-09-08
IL256423A (en) 2018-02-28
CR20180056A (es) 2018-05-25
US20220056010A1 (en) 2022-02-24
US11254649B2 (en) 2022-02-22
PH12017502414A1 (en) 2018-06-25
AR105483A1 (es) 2017-10-11
MA42301A (fr) 2018-05-09
TWI775187B (zh) 2022-08-21

Similar Documents

Publication Publication Date Title
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
PH12017502414A1 (en) Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
PH12018500259A1 (en) Muscarinic agonists
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY201629A (en) Benzopyrazole compounds and analogues thereof
EA201991884A2 (ru) Ингибиторы g12c kras
EA201690752A1 (ru) Ингибиторы g12c kras
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201390381A1 (ru) Триазиноксадиазолы
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2016005396A (es) Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades.
NZ726695A (en) Gls1 inhibitors for treating disease
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
ZA201907144B (en) Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
PH12016502568A1 (en) Novel heterocyclic compound

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2016, OBSERVADAS AS CONDICOES LEGAIS